Veidekke ASA: To build unique cancer centre in Aarhus
(Thomson Reuters ONE) -
Veidekke's Danish subsidiary Hoffmann has been awarded a contract to build a new
national research and treatment centre for particle therapy in Aarhus in
Jutland. This is a turnkey contract valued at DKK 280 million, excluding VAT.
The Danish Centre for Particle Therapy (DCPT) will be the only of its kind in
Denmark, and the centre will be one of the world's leading centres for research
and the treatment of cancer by particle-based radiation therapy. The new centre
will have 9,500 m(2) of floor space, and it will be built in connection with the
cancer ward at Aarhus University Hospital.
The actual building will be divided into a clinical section with CT and MRI
scanners and treatment rooms, and a bunker section that will house a proton
accelerator and three linear accelerators. To prevent radiation spreading to the
surroundings, concrete walls up to four metres thick will be cast with a very
advanced solution for ventilation, cooling and waste water collection.
Construction will start in February, and the building will be ready to receive
its first patient in September 2018.
For press photos, see www.flickr.com/photos/veidekke, for more information,
contact:
CEO Torben Bjørk Nielsen of Hoffmann, tel. +45 43 29 93 00, mobile
+45 60 12 93 00, tbn(at)hoffmann.dk
Communications Manager Helge Dieset of Veidekke, tel. +47 90 55 33 22,
helge.dieset(at)veidekke.no
Subscribe to notices from Veidekke
Veidekke is one of Scandinavia's largest construction and property development
companies. The company undertakes all types of building and construction
contracts, maintains roads and produces asphalt and aggregates. The company is
characterised by involvement and local knowledge. Revenue is NOK 24 billion
(2014), and half of the 6,400 employees own shares in the company. Veidekke is
listed on the Oslo Stock Exchange and has always posted a profit since it was
founded in 1936.
This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Illustration DCPT:
http://hugin.info/172/R/1955429/712046.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Veidekke ASA via GlobeNewswire
[HUG#1955429]
Unternehmensinformation / Kurzprofil:
Datum: 30.09.2015 - 09:01 Uhr
Sprache: Deutsch
News-ID 423570
Anzahl Zeichen: 2891
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 180 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Veidekke ASA: To build unique cancer centre in Aarhus"
steht unter der journalistisch-redaktionellen Verantwortung von
Veidekke ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
